クロストリディアルに支配された腸内微生物群は,コレスタシス治療において,オベチコル酸をリトコル酸に7α-デヒドロキシル化を促進する
Yuxuan Zhang1, Zhou Zhou1, Yunshu Li1
1State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, No.163 Xianlin Avenue, Nanjing 210023, China.
Biochemical and biophysical research communications
|September 4, 2025
まとめ
肝疾患におけるオベチコール酸 (OCA) の毒性は,それを有毒な代謝産物に変換する腸内細菌と関連している. 腸内微生物を調節することで,OCAを減らすことができる.
科学分野:
- 肝臓病と胃腸病
- 微生物群の研究
- 薬理学について
背景:
- オベチコール酸 (OCA) は胆固醇性肝疾患を治療しますが,投与量依存性肝毒性を引き起こします.
- OCAによる肝損傷の正確なメカニズムは不明である.
- 腸の機能障害はコレスタティック状態で観察される.
研究 の 目的:
- コレスタシス誘発性腸内不活性症とOCAの肝毒性とのメカニズム的関連を調査する.
- OCAの毒性プロファイルに 腸内微生物がどのように影響するかを明らかにする.
主な方法:
- コレスタシスの腸内微生物の構成を分析する
- OCAの代謝における微生物酵素の役割を調査する.
- 腸内細菌によるOCAのリトコール酸 (LCA) への変換の評価
主要な成果:
- コレスタシスは,クロストリジウム,バクテロイド,ラクトバシルスなどの属を好んで,腸内不活性化を引き起こす.
- 腸内細菌は7α-デヒドロキシラーゼを調節し,OCAを有毒な二次胆酸LCAに変換する.
- この微生物の生物活性化が,OCAの量依存性肝毒性を説明する.
結論:
- コレスタシスによる腸内不活性症,微生物による7α脱水酸化,およびOCAから有毒なLCAへの生物活性化との間には直接的な因果関係がある.
- 腸内微生物群はOCAの有効性と毒性を決定します
- 腸内微生物群をターゲットにすることで,OCAの肝毒性を軽減し,その安全性を高めることができます.
関連する概念動画
Drugs for Treatment of Constipation-Predominant IBS
322
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
322
Chronic Bowel Disorders: Introduction
536
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
536
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
319
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
319
Inflammatory Bowel Disease IV: Pharmacological Management
177
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
177
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
201
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
201
Drugs for Treatment of Diarrhea-Predominant IBS
289
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
289


